Product Description
ANB-033 is being developed by AnaptysBio for the treatment of autoimmune diseases. (Sourced from: https://www.anaptysbio.com/pipeline/anb033/)
Mechanisms of Action: IL2RB Antagonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AnaptysBio
Company Location: SAN DIEGO CA 92121
Company CEO: Daniel Faga
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|